Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group:: Comparison with the activities of 14 other agents

被引：25

作者：

Betriu, C ^{[1
]}

Gómez, M ^{[1
]}

Palau, ML ^{[1
]}

Sánchez, A ^{[1
]}

Picazo, JJ ^{[1
]}

机构：

[1] Hosp Clin San Carlos, Serv Microbiol Clin, Madrid 28040, Spain

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1999年 / 43卷 / 09期

关键词：

D O I：

10.1128/AAC.43.9.2320

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The antimicrobial activities of trovafloxacin, moxifloxacin, sanfetrinem, quinupristin-dalfopristin, and 14 other antimicrobial agents against 218 Bacteroides fragilis group strains were determined. A group of 10 imipenem-resistant strains were also tested. Imipenem, meropenem, and sanfetrinem had the lowest MICs of all of the beta-lactams. Quinupristin-dalfopristin inhibited all of the strains at 2 mu g/ml. Overall, the MICs of trovafloxacin and moxifloxacin for 90% of the strains tested were 1 and 2 mu g/ml, respectively.

引用

页码：2320 / 2322

页数：3

共 20 条

[11] Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria
Edlund, C
Sabouri, S
Nord, CE
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (03) : 193 - 195
[12] ANTIMICROBIAL RESISTANCE IN ANAEROBIC-BACTERIA - CURRENT SITUATION
GARCIARODRIGUEZ, JA
GARCIASANCHEZ, JE
MUNOZBELLIDO, JL
[J]. ANAEROBE, 1995, 1 (02) : 69 - 80
[13] In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds
Hoellman, DB
Spangler, SK
Jacobs, MR
Appelbaum, PC
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) : 495 - 501
[14] Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria
MacGowan, AP
Bowker, KE
Holt, HA
Wootton, M
Reeves, DS
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (04) : 503 - 509
[15] National Committee for Clinical Laboratory Standards, 1993, NCCLS PUBL
[16] SUSCEPTIBILITY OF ANAEROBIC-BACTERIA TO THE NEW STREPTOGRAMIN RP-59500 INVITRO
NORD, CE
LINDMARK, A
PERSSON, I
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (12) : 1064 - 1067
[17] Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994
Snydman, DR
McDermott, L
Cuchural, GJ
Hecht, DW
Iannini, PB
Harrell, LJ
Jenkins, SG
OKeefe, JP
Pierson, CL
Rihs, JD
Yu, VL
Finegold, SM
Gorbach, SL
[J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 : S54 - S65
[18] Analysis of the in vitro activity of trovafloxacin (CP-99,219) against Bacteroides species
Snydman, DR
McDermott, L
[J]. INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 : S96 - S100
[19] LONGITUDINAL-STUDY OF SUSCEPTIBILITIES OF SPECIES OF THE BACTEROIDES-FRAGILIS GROUP TO 5 ANTIMICROBIAL AGENTS IN 3 MEDICAL-CENTERS
TURGEON, P
TURGEON, V
GOURDEAU, M
DUBOIS, J
LAMOTHE, F
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) : 2276 - 2279
[20] In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria
Wexler, HM
Molitoris, E
Molitoris, D
Finegold, SM
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) : 2232 - 2235

← 1 2 →